Markets
U.S. open in 15 hrs, 44 mins
BUSINESS NEWS
- Market News
- Earnings
- Recalls
- Recession Watch
- Tech News
- Financial Crisis
- Madoff Scandal
- BloggingStocks
- Luxist
- Money Videos
INVESTING
- Stock Quotes
- Stock Charts
- Stock Ticker
- Currencies
- Portfolio
- Stock Screener
- Broker Center
- Mutual Fund Center
- ETF Center
- Money
- 24/7 Wall St.
- Financial Glossary
PERSONAL FINANCE AT WALLETPOP
- Bargains
- Banking
- Budget
- Calculators
- College Finance
- Community
- Credit
- Deals
- Debt
- Economizer
- Food
- Home
- Fraud
- Insurance
- Interest Rates
- Loans
- Mortgages
- Real Estate
- Recalls
- Recession
- Retirement
- Saving
- Simplification
- Specials
- Taxes
SMALL BUSINESS
Wide World of Stocks to Air on FOX Affiliates In New York and Los Angeles
Business Wire
The producers of a new program featuring microcap stocks, called
Wide
World of Stocks, have purchased air time on FOX affiliates in New
York and Los Angeles. A 30-minute taped episode about biotech firm Viral
Genetics (Pink Sheets: VRAL), will broadcast on WLNY, New York, on July
12 at 11:30 a.m. and 2:00 a.m. Eastern time. The same show, which
features the company’s CEO Haig Keledjian discussing Viral Genetics’
drug therapies for HIV/AIDs, Lyme Disease and cancer, will air on Los
Angeles’ KTTV on July 12 at 2:00 a.m. Pacific time.
The broadcast schedule is being updated as
Wide World of Stocks
producers purchase additional air time. It’s available at
www.wideworldofstocks.com,
where visitors also can register to receive alerts of additional
broadcasts. Episodes of
Wide World of Stocks will be available
for viewing at the site, after they have broadcast on network or cable
television.
The episode featuring Viral Genetics will be accessible to more than 100
million households through paid programming during July. During
interviews with the show’s host Damon Roberts and co-hosts Roland Rick
Perry and Thomas McCarthy, "The Dean" of CollegeStock.com, Mr. Keledjian
focused on the company’s international human clinical trials of a drug
compound that reduced the viral load and symptoms of HIV/AIDs. He also
discussed two recent additions to the company’s advisory board. Dr. Luc
Montagnier won a Nobel Prize in 2008 for his role in discovering HIV.
Dr. Leslie Z. Benet is an internationally recognized drug development
expert. Details are available at
www.viralgenetics.com.
About Viral Genetics, Inc.:
Viral Genetics, Inc. is engaged in the discovery and development of
immune-based therapies for HIV/AIDS and other autoimmune diseases using
its thymus nuclear protein compound (TNP). Viral Genetics believes that
its investigational HIV/AIDS drug based on TNP, called VGV-1, represents
a unique approach to treating HIV/AIDS that focuses on boosting the
immune system to allow the body to fight HIV more efficiently. See:
www.viralgenetics.com.
None of the information contained on this website is incorporated by
reference herein.
Not a Broker/Dealer or Financial
Advisor:
We are not a Registered Broker/Dealer or Financial Advisor, nor do we
hold ourselves out to be a Registered Broker/Dealer or Financial
Advisor. All materials presented in this press release, television show
and on our website are not to be regarded as investment advice and are
only for informative purposes. Readers should verify all claims and do
their own due diligence before investing in featured companies.
Investing
in small-cap, micro cap and penny stock securities is speculative and
carries a high degree of risk.
No Offer of Securities
:
None of the information featured in this press release constitutes an
offer or solicitation to purchase or to sell any securities of Viral
Genetics, Inc.
Current Ownership of Shares:
Affiliates of Wild World of Stocks, Inc. currently own securities of
Viral Genetics, Inc.
This is an inherent conflict of interest.
Compensation:
An Affiliate of Wide World of Stocks, Inc. has agreed to provide
consulting services to Viral Genetics, Inc. in exchange for up to 19
million shares of common stock and 12 million warrants of Viral
Genetics, Inc. upon the completion of certain milestones.
This is an
inherent conflict of interest. As of the date of this press release,
no shares of common stock or warrants have been issued pursuant to this
agreement.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
Information presented in this press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Exchange
Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any
statements that express or involve discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
goals, assumptions or future events or performance are not statements of
historical fact may be "forward-looking statements". Forward-looking
statements are based on expectations, estimates, and projections at the
time the statements are made that involve a number of risks and
uncertainties which could cause actual results or events to differ
materially from those presently anticipated. Forward-looking statements
in this action may be identified through use of words such as
"projects", "foresee", "expects", "will", "anticipates", "estimates",
"believes", "understands", or that by statements indicating certain
actions "may", "could", or "might" occur. Understand there is no
guarantee past performance will be indicative of future results.
None of the information contained on our website,
www.WideWorldofStocks.com,
is incorporated by reference herein.
Copyright Business Wire 2009
2009-07-08 12:44:00
COMMENTS ( 0 )
Latest Money News
CNNMoney
- White House, lenders, lawyers and borrowers: Nobody can agree on mortgage relief
- Tech IPO comeback: $50 billion in 2010?
- Thanksgiving Trade #6: SPDR S&P Homebuilders (XHB)
- The week in preview: Canadian banks, Aeropostale, Shanda Interactive ...
- Social media has impact on Black Friday for retailers and consumers